HCAT 📈 Health Catalyst - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42225T1079
HCAT: Data, Analytics, Software, Services, Healthcare
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah. Web URL: https://www.healthcatalyst.com
Additional Sources for HCAT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HCAT Stock Overview
Market Cap in USD | 537m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2019-07-25 |
HCAT Stock Ratings
Growth 5y | -82.4% |
Fundamental | -43.0% |
Dividend | - |
Rel. Strength Industry | -514 |
Analysts | 4.13/5 |
Fair Price Momentum | 5.22 USD |
Fair Price DCF | - |
HCAT Dividends
No Dividends PaidHCAT Growth Ratios
Growth Correlation 3m | -7.9% |
Growth Correlation 12m | -15.9% |
Growth Correlation 5y | -83.3% |
CAGR 5y | -27.94% |
CAGR/Mean DD 5y | -0.53 |
Sharpe Ratio 12m | -0.17 |
Alpha | -54.89 |
Beta | 1.14 |
Volatility | 67.46% |
Current Volume | 937.6k |
Average Volume 20d | 588.2k |
What is the price of HCAT stocks?
As of December 22, 2024, the stock is trading at USD 7.09 with a total of 937,597 shares traded.
Over the past week, the price has changed by -11.26%, over one month by -3.67%, over three months by -18.41% and over the past year by -21.31%.
As of December 22, 2024, the stock is trading at USD 7.09 with a total of 937,597 shares traded.
Over the past week, the price has changed by -11.26%, over one month by -3.67%, over three months by -18.41% and over the past year by -21.31%.
Is Health Catalyst a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Health Catalyst (NASDAQ:HCAT) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -42.97 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HCAT as of December 2024 is 5.22. This means that HCAT is currently overvalued and has a potential downside of -26.38%.
Probably not. Based on ValueRay Fundamental Analyses, Health Catalyst (NASDAQ:HCAT) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -42.97 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HCAT as of December 2024 is 5.22. This means that HCAT is currently overvalued and has a potential downside of -26.38%.
Is HCAT a buy, sell or hold?
Health Catalyst has received a consensus analysts rating of 4.13. Therefor, it is recommend to buy HCAT.
Health Catalyst has received a consensus analysts rating of 4.13. Therefor, it is recommend to buy HCAT.
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecast for HCAT stock price target?
According to ValueRays Forecast Model, HCAT Health Catalyst will be worth about 5.7 in December 2025. The stock is currently trading at 7.09. This means that the stock has a potential downside of -19.32%.
According to ValueRays Forecast Model, HCAT Health Catalyst will be worth about 5.7 in December 2025. The stock is currently trading at 7.09. This means that the stock has a potential downside of -19.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 11.6 | 64% |
Analysts Target Price | 14.7 | 106.9% |
ValueRay Target Price | 5.7 | -19.3% |